Eli Lilly Net Income/Loss 2012-2026 | LLY
Eli Lilly annual/quarterly net income/loss history and growth rate from 2012 to 2026. Net income/loss can be defined as the company's total income or loss before preferred stock dividends, taken from the Income Statement
- Eli Lilly net income/loss for the quarter ending March 31, 2026 was $20.640B, a 94.9% increase year-over-year.
- Eli Lilly net income/loss for the twelve months ending March 31, 2026 was $45.821B, a 89.16% increase year-over-year.
- Eli Lilly annual net income/loss for 2025 was $20.64B, a 94.9% increase from 2024.
- Eli Lilly annual net income/loss for 2024 was $10.59B, a 102.08% increase from 2023.
- Eli Lilly annual net income/loss for 2023 was $5.24B, a 16.08% decline from 2022.
|
Eli Lilly Annual Net Income/Loss (Millions of US $) |
|
|---|---|
| 2025 | $20,640 |
| 2024 | $10,590 |
| 2023 | $5,240 |
| 2022 | $6,245 |
| 2021 | $5,582 |
| 2020 | $6,194 |
| 2019 | $8,318 |
| 2018 | $3,232 |
| 2017 | $-204 |
| 2016 | $2,738 |
| 2015 | $2,408 |
| 2014 | $2,391 |
| 2013 | $4,685 |
| 2012 | $4,089 |
| 2011 | $4,348 |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Large Cap Pharmaceutical | $887.629B | $65.179B |
| Eli Lilly and Company, one of the world's largest pharmaceutical companies, boasts a diversified product profile including a solid lineup of new successful drugs. It also has a dependable pipeline as it navigates through challenges like patent expirations of several drugs and rising pricing pressure on its U.S. diabetes franchise. Its pharmaceutical product categories are neuroscience, diabetes, oncology, immunology and others. Over the past few years, Lilly has been actively seeking acquisitions and in-licensing deals to boost its product portfolio and pipeline. The purchase of ImClone Systems brought with it cancer compound, Erbitux. The acquisition of ICOS Corporation gave Lilly full control over erectile dysfunction drug, Cialis. Its other acquisitions include Hypnion, Inc., CoLucid Pharmaceuticals added Reyvow for acute migraine, Loxo Oncology and Dermira. Lilly has collaboration agreements with several companies including Incyte, Boehringer Ingelheim and Innovent Biologics among others. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Johnson & Johnson (JNJ) | United States | $574.358B | 22.08 |
| AbbVie (ABBV) | United States | $367.673B | 20.79 |
| Roche Holding AG (RHHBY) | Switzerland | $318.782B | 0.00 |
| Merck (MRK) | United States | $299.893B | 13.54 |
| Novartis AG (NVS) | Switzerland | $293.951B | 17.16 |
| Novo Nordisk (NVO) | Denmark | $167.527B | 9.60 |
| Pfizer (PFE) | United States | $153.074B | 8.33 |
| Sanofi (SNY) | France | $114.048B | 10.56 |
| Bayer (BAYRY) | Germany | $46.178B | 8.70 |
| Innoviva (INVA) | United States | $1.760B | 5.88 |